Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15295723 | 1.00 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2AHSD11B1 | |
| SCHEMBL16426507 | 1.00 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2AHSD11B1 | |
| SCHEMBL22946501 | 0.91 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2AHSD11B1 | |
| SCHEMBL28473882 | 0.81 | HSD11B1 (0.39) | MEN1ALDH1A1KMT2AHSD11B1CCR5 | |
| SCHEMBL15285474 | 0.81 | HPGD (0.45) | MEN1ALDH1A1KMT2A | |
| SCHEMBL22986774 | 0.81 | CTSK (0.35) | MEN1ALDH1A1TSHRKMT2AHSD11B1 | |
| SCHEMBL15295730 | 0.81 | CTSK (0.35) | MEN1ALDH1A1TSHRKMT2AHSD11B1 | |
| SCHEMBL16426508 | 0.80 | MEN1 (0.30) | MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL22946500 | 0.79 | CTSK (0.37) | MEN1ALDH1A1TSHRKMT2AHSD11B1 | |
| SCHEMBL16383192 | 0.79 | HSD11B1 (0.35) | MEN1ALDH1A1TSHRKMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210046057-A1 | Beta-lactamase inhibitor and use thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046057-A1 | Beta-lactamase inhibitor and use thereof | CYP51A1, LCT, CEL | MEN1 1764/4885ALDH1A1 316/4885TSHR 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.